Results 171 to 180 of about 2,198 (193)
Some of the next articles are maybe not open access.
Pralsetinib for the treatment of non-small cell lung cancer
Drugs of Today, 2021The identification of oncogenic drivers and the subsequent development of targeted therapies have been established as biomarker-based care for metastatic non-small cell lung cancer (NSCLC) patients. Rearranged during transfection (RET) events have been reported to be oncogenic drivers in NSCLC and were more common in patients who i) were young; ii) had
X-Y, Fu +5 more
openaire +2 more sources
Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC
Drugs, 2022Activating mutations in the proto-oncogene RET have been identified as an oncogenic driver of non-small cell lung cancer (NSCLC) in a small subset of patients. Pralsetinib (Gavreto®) is an orally-administered, next-generation, small-molecule selective RET inhibitor that is approved for the treatment of RET fusion-positive metastatic NSCLC.
openaire +2 more sources
Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
Cancer Discovery, 2021Abstract The crystal structures of these RET-bound TKIs showed that these drugs uniquely wrap around RET.
openaire +1 more source
Corneal edema and epithelial defect during pralsetinib treatment
Journal of Oncology Pharmacy PracticeIntroduction This article describes an unusual case of corneal edema with epithelial defect associated with pralsetinib, an oral rearranged during transfection (RET) inhibitor and used for the treatment of metastatic RET fusion-positive non–small cell lung cancer (NSCLC). Case report
Neslihan Bayraktar Bilen +2 more
openaire +1 more source